FindTrial
Sign In

Neoadjuvant Chemotherapy (NACT)

DRUG7 trials

Sponsors

Professor Fernando Figueira Integral Medicine Institute, Hubei Cancer Hospital, RenJi Hospital, Fudan University, Shanghai Zhongshan Hospital

Conditions

BRCA 1 Gene MutationBRCA 2 Gene MutationBreast Cancer (Early Breast Cancer)CTLA4Esophageal CancerHR+/HER2- Breast CancerHypopharyngeal CarcinomaLaryngeal Carcinoma

Phase 2

Short-course HIPEC in Advanced Epithelial Ovarian Cancer
CompletedNCT02249013
Professor Fernando Figueira Integral Medicine InstituteOvarian Cancer
Start: 2015-02-28End: 2021-02-23Updated: 2021-03-18
Neoadjuvant Chemo-immunotherapy Followed by Concurrent Chemoradiotherapy and Immunotherapy in LACC
Not yet recruitingNCT06916117
RenJi HospitalLocally Advanced Cervical Cancer
Start: 2025-04-05End: 2028-12-30Target: 30Updated: 2025-04-08
Combined Chemo-immunotherapy Plus SBRT in Neoadjuvant Treatment for Luminal Subtype Breast Cancer
Not yet recruitingNCT07254858
First Affiliated Hospital of Wenzhou Medical UniversityHR+/HER2- Breast Cancer
Start: 2025-12-31End: 2029-12-30Target: 302Updated: 2025-11-28

Phase 3

Comparing Neoadjuvant Chemotherapy Combined With PD-1 Inhibitor Versus Neoadjuvant Chemotherapy in Locally Advanced Laryngeal and Hypopharyngeal Carcinoma
Not yet recruitingNCT06957938
Fudan UniversityHypopharyngeal Carcinoma, Laryngeal Carcinoma
Start: 2025-04-28End: 2031-05-01Target: 168Updated: 2025-05-08

Unknown Phase

CNCMT：a Multi-center, Prospective, Single-arm Study
Enrolling by invitationNCT06714084
Hubei Cancer HospitalCTLA4, Locally Advanced Cervical Cancer, PD1
Start: 2024-10-08End: 2026-12-31Target: 20Updated: 2026-09-18
Patient Derived Organoids (PDOs) to Observe the Clinical Consistency of Personalized Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma
RecruitingNCT07054086
Shanghai Zhongshan HospitalEsophageal Cancer
Start: 2025-03-01End: 2026-07-31Target: 30Updated: 2025-07-08
Combination of Mitomycin and Carboplatin in Neoadjuvant Therapy in BRCA-associated Triple-negative Locally Advanced Breast Cancer
Active, not recruitingNCT07821229
N.N. Petrov National Medical Research Center of OncologyBRCA 1 Gene Mutation, BRCA 2 Gene Mutation, Breast Cancer (Early Breast Cancer)
Start: 2022-09-27End: 2030-12-01Target: 30Updated: 2026-09-15

Related Papers

Quality of life in a phase 2 trial of short-course hyperthermic intraperitoneal chemotherapy (HIPEC) at interval debulking surgery for high tumor burden ovarian cancer
Revista do Colégio Brasileiro de Cirurgiões2020-01-018 citations
388 Short-course HIPEC at the time of interval debulking surgery for high tumor burden ovarian cancer: preliminary results of a pioneering clinical trial in brazil
2019-09-01
Neoadjuvant chemotherapy followed by fast-track cytoreductive surgery plus short-course hyperthermic intraperitoneal chemotherapy (HIPEC) in advanced ovarian cancer: preliminary results of a promising all-in-one approach.
2017-12-139 citations
Exploring flow rate selection in HIPEC procedures
Revista do Colégio Brasileiro de Cirurgiões2016-12-017 citations